Evidence map›Paper›PMID 27812879›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2017

Senescence-Like Phenotypes in Human Nevi.

Andrew Joselow, Darren Lynn, Tamara Terzian, Neil F Box

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Aberrant expression of p16Cancer reports and reviews · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Andrew JoselowCharles C. Gates Center for Regenerative Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Darren LynnCharles C. Gates Center for Regenerative Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Tamara TerzianCharles C. Gates Center for Regenerative Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Neil F BoxDepartment of Dermatology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. neil.box@ucdenver.edu.
University of Colorado Anschutz Medical Campus · USTulane University · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
SKIN CANCER PREVENTION IN A PEDIATRIC POPULATIONR01CA074592 · NCI · UNIVERSITY OF COLORADO DENVER · PI BOX, NEIL FREDERICK, CRANE, LORI A. · 1997 to 2014
$5.2M
KLF9-TXNRD2 axis in melanoma progression and metastasisR01CA190533 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI NIKIFOROV, MIKHAIL · 2015 to 2019
$2.0M
Targeting p53-Dependent Repigmentation in VitiligoK01AR063203 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI TERZIAN, TAMARA G · 2012 to 2016
$503k
The role of keratinocyte p53 in development of pigmented lesionsR03AR066880 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI BOX, NEIL FREDERICK · 2015 to 2017
$233k
p53 in MelanomagenesisR03CA191937 · NCI · UNIVERSITY OF COLORADO DENVER · PI TERZIAN, TAMARA G · 2016 to 2017
$156k
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA074592NCI NIH HHS R01 CA190533NCI NIH HHS R03 CA191937NCRR NIH HHS UL1 RR025780NIAMS NIH HHS K01 AR063203NIAMS NIH HHS R03 AR066880
6 · The paper itself

Abstract

Cellular senescence is an irreversible arrest of cell proliferation at the G1 stage of the cell cycle in which cells become refractory to growth stimuli. Senescence is a critical and potent defense mechanism that mammalian cells use to suppress tumors. While there are many ways to induce a senescence response, oncogene-induced senescence (OIS) remains the key to inhibiting progression of cells that have acquired oncogenic mutations. In primary cells in culture, OIS induces a set of measurable phenotypic and behavioral changes, in addition to cell cycle exit. Senescence-associated β-Galactosidase (SA-β-Gal) activity is a main hallmark of senescent cells, along with morphological changes that may depend on the oncogene that is activated, or on the primary cell type. Characteristic cellular changes of senescence include increased size, flattening, multinucleation, and extensive vacuolation. At the molecular level, tumor suppressor genes such as p53 and p16

Indexed as

Cellular Senescencebeta-GalactosidaseBiomarkersCell LineCells, CulturedCyclin-Dependent Kinase Inhibitor p16Gene ExpressionHumansImmunohistochemistryNevusPhenotypeProto-Oncogene Proteins B-rafSkin NeoplasmsTumor Suppressor Protein p53beta-GalactosidaseBiomarkersCyclin-Dependent Kinase Inhibitor p16Proto-Oncogene Proteins B-rafTumor Suppressor Protein p53BRAFCancerDNA damageGalactosidaseImmunofluorescenceMelanomaNevusOncogenep16INK4Ap53ProtocolSenescence

Identifiers

PMID27812879
PMCPMC5125895
OpenAlexW2547703722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.